JP2022551282A5 - - Google Patents

Info

Publication number
JP2022551282A5
JP2022551282A5 JP2022520724A JP2022520724A JP2022551282A5 JP 2022551282 A5 JP2022551282 A5 JP 2022551282A5 JP 2022520724 A JP2022520724 A JP 2022520724A JP 2022520724 A JP2022520724 A JP 2022520724A JP 2022551282 A5 JP2022551282 A5 JP 2022551282A5
Authority
JP
Japan
Prior art keywords
cysteine
approximately
composition according
absent
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520724A
Other languages
English (en)
Japanese (ja)
Other versions
JP7761557B2 (ja
JP2022551282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2020/013467 external-priority patent/WO2021066600A1/ko
Publication of JP2022551282A publication Critical patent/JP2022551282A/ja
Publication of JP2022551282A5 publication Critical patent/JP2022551282A5/ja
Priority to JP2025107100A priority Critical patent/JP2025144567A/ja
Application granted granted Critical
Publication of JP7761557B2 publication Critical patent/JP7761557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520724A 2019-10-04 2020-10-05 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 Active JP7761557B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107100A JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190123250 2019-10-04
KR10-2019-0123250 2019-10-04
PCT/KR2020/013467 WO2021066600A1 (ko) 2019-10-04 2020-10-05 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107100A Division JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Publications (3)

Publication Number Publication Date
JP2022551282A JP2022551282A (ja) 2022-12-08
JP2022551282A5 true JP2022551282A5 (OSRAM) 2023-10-16
JP7761557B2 JP7761557B2 (ja) 2025-10-28

Family

ID=75338451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520724A Active JP7761557B2 (ja) 2019-10-04 2020-10-05 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
JP2025107100A Abandoned JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107100A Abandoned JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Country Status (6)

Country Link
US (1) US20230000950A1 (OSRAM)
EP (1) EP4043026A4 (OSRAM)
JP (2) JP7761557B2 (OSRAM)
KR (1) KR20210040818A (OSRAM)
CN (1) CN114786706A (OSRAM)
WO (1) WO2021066600A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080986A1 (ko) 2020-10-16 2022-04-21 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022254588A1 (en) * 2021-04-09 2023-09-21 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN116120403B (zh) * 2022-11-01 2026-03-17 成都普康唯新生物科技有限公司 一种固相制备Tirzepatide的方法
CN117756913B (zh) * 2022-11-07 2025-05-09 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN116942612A (zh) * 2023-08-30 2023-10-27 重庆派金生物科技有限公司 一种脂肪酸修饰的胰高血糖素样肽类似物的鼻用喷雾剂及其应用
WO2025101959A1 (en) * 2023-11-08 2025-05-15 Renbio, Inc. Plasmid dna constructs for peptide hormone expression
KR20250177375A (ko) * 2024-06-13 2025-12-23 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
AU2014345569B2 (en) * 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP3080150B1 (en) * 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) * 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TN2017000555A1 (en) * 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
SG11201811697SA (en) * 2016-06-29 2019-01-30 Hanmi Pharmaceutical Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
AR110301A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
US20210338779A1 (en) * 2018-10-04 2021-11-04 Hanmi Pharm. Co., Ltd Therapeutic use of glucagon and combination including the same

Similar Documents

Publication Publication Date Title
JP6694013B2 (ja) オキシントモジュリンと免疫グロブリンのフラグメントとを含むタンパク質結合体の液状製剤
JP6936366B2 (ja) 胆汁酸に関係した障害の治療方法
JP7322105B2 (ja) 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
RU2671088C2 (ru) Агонисты рецепторов глюкагона/glp-1 для лечения ожирения
JP6898231B6 (ja) Ｇｉｐアゴニスト化合物及び方法
JP7761557B2 (ja) グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
TWI708614B (zh) 包含調酸素衍生物之治療高血脂症的組成物
JP2021518745A5 (ja) アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
JP2025114622A (ja) 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
JP2022509568A5 (OSRAM)
JP2018526333A5 (OSRAM)
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
CN107849110A (zh) 选择性pyy化合物及其用途
CN104302772A (zh) 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
JP2015504073A5 (OSRAM)
JP2018504901A5 (OSRAM)
JP2025178483A (ja) ポリペプチドを含む医薬組成物
JP2018505153A (ja) グルカゴン誘導体
JP2023538236A5 (OSRAM)
TWI889865B (zh) 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途
JP2013511287A (ja) ポリペプチド・コンジュゲート
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
JP2024512895A5 (OSRAM)
JP2022535685A (ja) ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物
JP2025500508A5 (OSRAM)